Market Cap
₹147.3b
Last Updated
2019/10/21 12:34 UTC
Data Sources
Company Financials +
Executive Summary
Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally.
Snowflake
Fundamentals
Excellent balance sheet with acceptable track record.
Similar Companies
Share Price & News
How has Pfizer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.6%
500680
3.9%
IN Pharmaceuticals
3.8%
IN Market
1 Year Return
16.9%
500680
-17.5%
IN Pharmaceuticals
6.0%
IN Market
Return vs Industry: 500680 exceeded the Indian Pharmaceuticals industry which returned -17.5% over the past year.
Return vs Market: 500680 exceeded the Indian Market which returned 6% over the past year.
Shareholder returns
| 500680 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.6% | 3.9% | 3.8% |
| 30 Day | -2.1% | -4.4% | 2.9% |
| 90 Day | 0.03% | -2.0% | 2.9% |
| 1 Year | 17.8%16.9% | -16.8%-17.5% | 8.2%6.0% |
| 3 Year | 79.9%75.6% | -25.4%-27.0% | 23.0%16.7% |
| 5 Year | 107.7%99.8% | -10.5%-13.2% | 43.6%30.0% |
Price Volatility Vs. Market
How volatile is Pfizer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
How Pfizer Limited (BOM:500680) Delivered A Better ROE Than Its IndustryValuation
Is Pfizer undervalued compared to its fair value and its price relative to the market?
32.72x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500680 (₹3218.75) is trading above our estimate of fair value (₹357.19)
Significantly Below Fair Value: 500680 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500680 is poor value based on its PE Ratio (32.7x) compared to the Pharmaceuticals industry average (15.7x).
PE vs Market: 500680 is poor value based on its PE Ratio (32.7x) compared to the Indian market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: 500680 is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: 500680 is overvalued based on its PB Ratio (4.9x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
11.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500680's forecast earnings growth (11.3% per year) is above the savings rate (7.6%).
Earnings vs Market: 500680's earnings (11.3% per year) are forecast to grow slower than the Indian market (18% per year).
High Growth Earnings: 500680's earnings are forecast to grow, but not significantly.
Revenue vs Market: 500680's revenue (11.3% per year) is forecast to grow slower than the Indian market (11.3% per year).
High Growth Revenue: 500680's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 500680's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Pfizer performed over the past 5 years?
25.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 500680's earnings have grown significantly by 25.4% per year over the past 5 years.
Accelerating Growth: 500680's earnings growth over the past year (14%) is below its 5-year average (25.4% per year).
Earnings vs Industry: 500680 earnings growth over the past year (14%) underperformed the Pharmaceuticals industry 14.4%.
Return on Equity
High ROE: 500680's Return on Equity (14.9%) is considered low.
Return on Assets
ROA vs Industry: 500680 has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 500680 has significantly improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Pfizer's financial position?
Financial Position Analysis
Short Term Liabilities: 500680's short term assets (₹27.2B) exceeds its short term liabilities (₹8.9B)
Long Term Liabilities: 500680's short term assets (27.2B) exceeds its long term liabilities (369.6M)
Debt to Equity History and Analysis
Debt Level: 500680's debt to equity ratio (0.08%) is considered satisfactory
Reducing Debt: Insufficient data to determine if 500680's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 500680's debt is well covered by operating cash flow (3912.4%).
Interest Coverage: 500680 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: 500680 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 500680's debt is covered by short term assets (assets are 1086.668000x debt).
Next Steps
Dividend
What is Pfizer's current dividend yield, its reliability and sustainability?
0.70%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 500680's dividend (0.7%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: 500680's dividend (0.7%) is low compared to the top 25% of dividend payers in the Indian market (2.42%).
Stable Dividend: 500680's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500680's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (22.9%), 500680's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of Pfizer's salary, the management and board of directors tenure and is there insider trading?
6.7yrs
Average management tenure
CEO
S. Sridhar (51yo)
3.6yrs
Tenure
₹35,526,571
Compensation
Mr. S. Sridhar has been the Chief Executive Officer, Managing Director & Lead – Essential Health Portfolio of Pfizer Limited since March 18, 2016. Mr. Sridhar served as Business Unit Head of Pfizer Limited ...
CEO Compensation Analysis
Compensation vs. Market: S.'s total compensation ($USD499.84K) is about average for companies of similar size in the Indian market ($USD621.42K).
Compensation vs Earnings: S.'s compensation has been consistent with company performance over the past year.
Management Age and Tenure
6.7yrs
Average Tenure
52yo
Average Age
Experienced Management: 500680's management team is seasoned and experienced (6.7 years average tenure).
Board Age and Tenure
6.4yrs
Average Tenure
57yo
Average Age
Experienced Board: 500680's board of directors are considered experienced (6.4 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Prajeet Nair
Compliance Officer & Company Secretary
- Tenure: 12.1yrs
- Compensation: ₹5.35m
S. Sridhar (51yo)
CEO, MD
- Tenure: 3.6yrs
- Compensation: ₹35.53m
Samir Kazi
Senior Director of Legal
- Tenure: 9.8yrs
Vivek Dhariwal (52yo)
Executive Director of Technical Operations & Whole-Time Director
- Tenure: 7.4yrs
- Compensation: ₹25.25m
Sharad Goswami
Senior Director of Public Affairs
- Tenure: 0yrs
Milind Patil (55yo)
CFO, Executive Director of Finance & Executive Director
- Tenure: 0.9yrs
- Compensation: ₹9.94m
Shilpi Singh
Director of Human Resources
- Tenure: 0yrs
Board Members
Meena Ganesh (55yo)
Additional Independent Director
- Tenure: 0.6yrs
- Compensation: ₹150.00k
Rajendra Shah (88yo)
Non Executive Independent Chairman
- Tenure: 0yrs
- Compensation: ₹2.20m
Sunil Lalbhai (59yo)
Non Executive Independent Director
- Tenure: 4.7yrs
- Compensation: ₹1.86m
Pradip Shah (66yo)
Non-Executive Independent Director
- Tenure: 19.8yrs
- Compensation: ₹2.29m
Uday Khanna (70yo)
Non Executive Independent Director
- Tenure: 7.4yrs
- Compensation: ₹2.23m
S. Sridhar (51yo)
CEO, MD
- Tenure: 3.6yrs
- Compensation: ₹35.53m
Vivek Dhariwal (52yo)
Executive Director of Technical Operations & Whole-Time Director
- Tenure: 7.4yrs
- Compensation: ₹25.25m
Milind Patil (55yo)
CFO, Executive Director of Finance & Executive Director
- Tenure: 0.9yrs
- Compensation: ₹9.94m
Company Information
Pfizer Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Pfizer Limited
- Ticker: 500680
- Exchange: BSE
- Founded: 1950
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹147.251b
- Shares outstanding: 45.75m
- Website: https://www.pfizerindia.com
Number of Employees
Location
- Pfizer Limited
- The Capital
- 1802 / 1901, 18th Floor
- Mumbai
- Maharashtra
- 400051
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 500680 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Mar 1999 |
| PFIZER | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Mar 1999 |
Biography
Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its various products in various therapeutic areas, including anti-allergic, anti ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/21 12:34 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.